Medical Information

Veozah is a selective estrogen receptor degrading agent (SERD), which is mainly used to treat ER+/HER2 advanced breast cancer. It exerts anti-tumor effects by blocking the estrogen receptor signaling pathway, requiring strict adherence to individualized dosing regimens and monitoring of medication risks in special populations.

1. Standard usage and dosage

(1) Medication regimen

Take 30mg orally once a day, and it is recommended to take it at a fixed time. Tablets should be swallowed whole and should not be crushed or chewed.

(2) Course management

Continue treatment until disease progression or intolerable toxicity occurs. The first efficacy evaluation should undergo imaging examination at 8-12 weeks.

(3) Dose adjustment

When adverse reactions of grade ≥ 3 occur, treatment should be interrupted and reduced to 20mg/day after recovery to grade ≤ 1. Only one reduction is allowed.

2. Medication for special populations

(1) Pregnancy period

Animal studies have shown embryo fetal toxicity, and pregnant women should avoid using it. Effective contraception is required for women of childbearing age during treatment and within 3 weeks after the last dose.

(2) Lactation period

There is currently no data on whether the medication is secreted into breast milk. It is recommended to suspend breastfeeding during the treatment period and within one month after discontinuing the medication.

(3) Liver dysfunction

Mild injury (Child Pugh A) does not require dose adjustment; The recommended dose for moderate to severe injuries (Child Pugh B/C) is reduced to 20mg/day.

(4) Renal insufficiency

Mild to moderate injury (eGFR ≥ 30mL/min) does not require adjustment; There is a lack of data for patients with severe injury (eGFR<30mL/min) or dialysis.

(5) Elderly patients

Patients aged 65 and above do not need to adjust the dosage, but need to strengthen QT interval monitoring. 28% of patients in clinical studies are aged ≥ 70 years old.

3. Important precautions

(1) Cardiac toxicity

Baseline electrocardiogram is required before treatment, and QT interval should be monitored regularly. Avoid using other drugs that prolong the QT interval in combination.

(2) Drug interactions

CYP3A4 potent inhibitors should be avoided in combination; If necessary, non zolpidem should be reduced to 20mg/day.

(3) Laboratory monitoring

Monthly monitoring of blood routine and liver and kidney function. If grade ≥ 2 hematological toxicity occurs, administration should be suspended.